🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for CLL/SLL

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT07557056Phase 21 site📍 Columbus Jennifer Woyach · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Nemtabrutinib Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients NCT05876923NA2 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry, Electronic Health Record Review, E… Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies NCT07648264Phase 360 sites📍 Orange📍 Denver📍 Coral Springs CSL Behring · Tests: IgPro20 Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235NA1 site📍 New Hyde Park Northwell Health · Tests: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06588478Phase 2131 sites📍 Chandler📍 Duarte📍 Irvine Loxo Oncology, Inc. · Tests: Pirtobrutinib Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT06757647Phase 21 site📍 Columbus Seema Bhat · Tests: Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Los Angeles AVM Biotechnology Inc · Tests: AVM0703 Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) NCT07509151Phase 344 sites📍 La Jolla📍 Denver📍 New Haven AstraZeneca · Tests: Surovatamig Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Mosunetuzumab for CLL MRD Clearance NCT07052695Phase 1, Phase 22 sites📍 Boston📍 Boston Inhye Ahn · Tests: Mosunetuzumab, Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia NCT04704323Phase 14 sites📍 Boston📍 Durham📍 Madrid Catapult Therapeutics · Tests: CAP-100 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038Phase 1, Phase 265 sites📍 Boston📍 Hackensack📍 New Brunswick AstraZeneca · Tests: Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting NCT06788639n/a1 site📍 Milwaukee Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: Lisocabtagene maraleucel Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL NCT07014917Phase 21 site📍 Cincinnati Zulfa Omer · Tests: Venetoclax, Acalabrutinib, Venetoclax, Acalabrutinib Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCT04223765Phase 11 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: CAR.k.28, Fludarabine, Cyclophosphamide, Bendamustine A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients NCT07671378Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Zanubrutinib and sonrotoclax Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia NCT07685717Phase 21 site📍 Columbus Jennifer Woyach · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib NCT07428707EARLY Phase 11 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: Pirtobrutinib Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia NCT05336812Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Acalabrutinib, Obinutuzumab, Venetoclax Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902Phase 3632 sites📍 Birmingham📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Obinutuzumab Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma NCT06839053Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT06859008Phase 11 site📍 Duarte City of Hope Medical Center · Tests: Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03) NCT06378138Phase 2, Phase 353 sites📍 Bengbu📍 Hefei📍 Hefei Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-248, Orelabrutinib Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab NCT07024706Phase 247 sites📍 Boston📍 Charlotte📍 Charlotte AstraZeneca · Tests: Acalabrutinib, Venetoclax Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial NCT04941716Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy